Benzisothiazolinone

Isothiazolinone-class preservative emerging as a replacement for methylisothiazolinone (MI) following the EU ban. As MI has been removed from intimate wipes and personal care, BIT usage has increased and early sensitization signals are appearing in clinical patch-test surveillance. Structurally related to MI/MCI with potential for cross-reactivity in MI-sensitized individuals and independent sensitization. Identified as an emerging concern in intimate care contexts by clinical reviewers. Formulators should monitor dermatological society position statements and consider non-isothiazolinone preservation alternatives for intimate wipe products.

Permitted; EPA-registered biocide. Early sensitization signals emerging in patch-test clinical surveillance as use volume increases following MI restrictions.